论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
Authors Chen K, Gao Y, Shi F, Cao G, Bao J
Received 25 May 2017
Accepted for publication 11 November 2017
Published 19 January 2018 Volume 2018:11 Pages 459—463
DOI https://doi.org/10.2147/OTT.S142598
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Colin Mak
Peer reviewer comments 3
Editor who approved publication: Dr William Cho
Abstract: Medullary thyroid carcinoma (MTC) is a rare malignancy originating
from calcitonin-producing parafollicular C cells of the thyroid. Neither
radiotherapy nor chemotherapy has demonstrated durable objective responses in
patients with advanced MTC. Vandetanib and cabozantinib are the 2 tyrosine
kinase inhibitors recently approved by the US Food and Drug Administration,
which are not affordable for most Chinese patients. Herein, we report a case of
an MTC patient who responded to apatinib, a Chinese homemade tyrosine kinase
inhibitor-targeted vascular endothelial growth factor receptor. The patient was
treated with thyroid lobectomy but developed MTC with extensive metastasis. The
levels of serum calcitonin and carcino-embryonic antigen were much higher than
the normal range. Apatinib was given at a dose of 500 mg daily and adjusted
according to tolerance. Sixteen weeks following apatinib administration, the
patient achieved a partial response, which lasted more than 9 weeks. No severe
toxicity or drug-related side effect was observed during the treatment.
Therefore, apatinib could be a new option for the treatment of advanced MTC.
Keywords: apatinib,
tyrosine kinase inhibitors, advanced medullary thyroid carcinoma